Last reviewed · How we verify
KIN-1901
At a glance
| Generic name | KIN-1901 |
|---|---|
| Sponsor | Kinevant Sciences GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) (PHASE2)
- Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KIN-1901 CI brief — competitive landscape report
- KIN-1901 updates RSS · CI watch RSS
- Kinevant Sciences GmbH portfolio CI